GlucoTrack (GCTK) Q4 2025 earnings summary

Executive summary

• Advanced development of fully implantable continuous blood glucose monitoring (CBGM) technology, targeting a US clinical trial launch in the second half of 2026.

• Strengthened intellectual property with three new USPTO patents for CBGM platform, covering sensor chemistry, intravascular lead design, and low-power electronics.

• Completed a $4.0 million private placement to support working capital and corporate purposes.

• Initiated a multicenter feasibility study in Australia and prepared for US IDE submission in Q2 2026.

Financial highlights

• Research and development expenses were $9.8 million for 2025, up from $9.5 million in 2024, due to increased product development and pre-clinical studies.

• General and administrative expenses rose to $6.3 million from $5.1 million year-over-year, mainly from higher professional fees and personnel costs.

• Net loss for 2025 was $19.4 million, an improvement from $22.6 million in 2024, primarily due to non-cash losses in the prior year.

• Cash and cash equivalents at year-end 2025 were $7.4 million, up from $5.6 million at year-end 2024, reflecting $17.0 million in financing activities offset by $15.3 million in operating and investing outflows.

Outlook and guidance

• Existing cash and equivalents are expected to fund operations through spring 2026, supporting IDE submission and initiation of US clinical trials.

• IDE submission to FDA planned for Q2 2026, with US clinical trial launch anticipated in the second half of 2026.

• Plans to present additional clinical data and expand advisory boards with experts in endocrinology and cardiology.